Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
9Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Mineralys Therapeutics, Inc. (MLYS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
16Total relationships
4Distinct source URLs
7High confidence
0.744Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Mineralys Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
TANABE-PHARMA-CORPORATION
TANABE-PHARMA-CORPORATION
92%
Under the Amendment, the license granted by Tanabe to the Company related to lorundrostat was amended and restated to grant to the Company an exclusive, worldwide, royalty-free, sublicensable, perpet…
MITSUBISHI-TANABE
MITSUBISHI-TANABE
90%
Pursuant to the Mitsubishi License, we paid Mitsubishi Tanabe a $1.0 million upfront fee and development milestone payments of $9.0 million in the aggregate.
TANABE
TANABE
90%
Pursuant to the Tanabe License, we paid Tanabe a $1.0 million upfront fee and development milestone payments of $9.0 million in the aggregate.
Reciprocal relationship from BAC graph: Reciprocal relationship from MLYS graph: Reciprocal relationship from BAC graph: Reciprocal relationship from MLYS graph: ear, depending on the timing of our c…
BOFA-SECURITIES-INC
BOFA-SECURITIES-INC
62%
ear, depending on the timing of our clinical development activities and other research and development activities. We expect our expenses and operating losses will increase substantially as we conduc…
BOFA-SECURITIES-INC-EVERCORE-GROUP
BOFA-SECURITIES-INC-EVERCORE-GROUP
62%
ear, depending on the timing of our clinical development activities and other research and development activities. We expect our expenses and operating losses will increase substantially as we conduc…
CO-LLC
CO-LLC
62%
ear, depending on the timing of our clinical development activities and other research and development activities. We expect our expenses and operating losses will increase substantially as we conduc…
EVERCORE-GROUP
EVERCORE-GROUP
62%
ear, depending on the timing of our clinical development activities and other research and development activities. We expect our expenses and operating losses will increase substantially as we conduc…
Reciprocal relationship from EVR graph: Reciprocal relationship from MLYS graph: Reciprocal relationship from EVR graph: Reciprocal relationship from MLYS graph: ear, depending on the timing of our c…
F-9-MINERALYS-THERAPEUTICS-INC
F-9-MINERALYS-THERAPEUTICS-INC
62%
mounts held primarily in interest-bearing money market accounts and U.S. Treasury bills with original maturities of less than three months. The Company’s cash and cash equivalents balances as of Dece…
MITSUBISHI-TANABE-PHARMA-CORPORATION
MITSUBISHI-TANABE-PHARMA-CORPORATION
62%
oing regulatory activities, including responding to FDA information requests, supporting a potential advisory committee meeting (not anticipated currently), preparing for potential approval and post-…
TANABE-PHARMA-CORPORATION
TANABE-PHARMA-CORPORATION
62%
oing regulatory activities, including responding to FDA information requests, supporting a potential advisory committee meeting (not anticipated currently), preparing for potential approval and post-…
Mineralys Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
MLYS-DEBT
Debt stack $100,000
90%
Market cache reports total debt of $100,000.
MLYS-DEBT-11018
Warrants outstanding: 0.001
90%
xbrl warrant detail from xbrl 2024-02-07.
MLYS-DEBT-11019
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
Mineralys Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Mineralys Therapeutics, Inc..
Mineralys Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
MLYS-OWNER-CATALYS-PACIFIC-LLC
Catalys Pacific, LLC
90%
13F overlay lists Catalys Pacific, LLC as top holder; 217 tracked holders.
Mineralys Therapeutics, Inc. Extended Supply Chain Network
